Ketamine relaxes airway smooth muscle and has been used for decades as a rescue treatment in severe asthma attacks that fail to respond to standard bronchodilators and steroids. The drug works through several mechanisms that are distinct from conventional asthma medications, making it an appealing option when everything else has failed. Yet the clinical evidence is more complicated than the pharmacology would suggest: while dramatic case reports describe patients pulled back from the brink of mechanical ventilation, randomized controlled trials have largely failed to show a clear benefit over standard care. That gap between what ketamine does in the lab and what it consistently delivers at the bedside is the central tension in this topic.
How Ketamine Opens Constricted Airways
When an asthma attack tightens the smooth muscle wrapped around the bronchial tubes, most rescue drugs work by stimulating beta-2 receptors on those muscle cells, essentially telling them to relax. Ketamine takes a different route. Research in animal airway tissue has shown that ketamine lowers the concentration of calcium inside smooth muscle cells and reduces calcium flowing in through voltage-dependent channels. Since calcium is what drives the muscle contraction in the first place, blocking its entry loosens the squeeze on the airways.1PubMed. Calcium concentration-dependent mechanisms through which ketamine relaxes canine airway smooth muscle Studies in porcine tracheal tissue confirmed that ketamine inhibits these voltage-dependent calcium channels directly.2Anesthesiology. Inhibitory Effects of Thiopental, Ketamine, and Propofol on Voltage-dependent Calcium 2+ Channels in Porcine Tracheal Smooth Muscle Cells
Ketamine also boosts the body’s own bronchodilators. It blocks the reuptake of norepinephrine at nerve endings, which raises the level of circulating catecholamines. Those catecholamines then stimulate the same beta-2 receptors that conventional inhalers target. Animal studies demonstrated that the peak bronchodilatory effect of ketamine tracks with rising norepinephrine levels, and that blocking beta receptors with propranolol wipes out the protective effect entirely.3PubMed Central. Ketamine in status asthmaticus: A review Classic dog studies of experimental asthma confirmed this: animals anesthetized with ketamine showed almost no increase in airway resistance after an asthma-triggering exposure, while animals given a different anesthetic saw their resistance spike roughly fourfold. When the researchers added propranolol to block beta receptors, ketamine lost its protective effect completely.4BJA: British Journal of Anaesthesia. KETAMINE BLOCK OF BRONCHOSPASM IN EXPERIMENTAL CANINE ASTHMA
Interestingly, while ketamine is best known as an NMDA receptor blocker (that is how it produces anesthesia and its dissociative effects), the airway relaxation does not appear to work through NMDA receptors at all. When researchers tested other NMDA-blocking drugs on histamine-constricted tracheal tissue, they too could reverse the contraction, but neither an NMDA agonist nor MK-801 (a potent NMDA blocker) could mimic or alter ketamine’s specific relaxation pattern. The conclusion: ketamine’s effect on airways is independent of its most famous receptor target.5PubMed. The role of the N-methyl-D-aspartic acid receptor in the relaxant effect of ketamine on tracheal smooth muscle
Anti-Inflammatory Effects Beyond Bronchodilation
Asthma is not just muscle spasm. The airway lining is inflamed, swollen, and choked with immune cells, particularly eosinophils and neutrophils in severe attacks. Newer research suggests ketamine may address this inflammatory side of asthma, too. In a mouse model of mixed-type asthma, ketamine reduced eosinophil and neutrophil counts in lung fluid, decreased oxidative stress markers, and activated the Nrf2 pathway, a cellular defense system against inflammation and oxidative damage. The drug appeared to trigger programmed cell death in those inflammatory cells, effectively clearing them from the airways.6PubMed Central. Ketamine Attenuates Airway Inflammation via Inducing Inflammatory Cells Apoptosis and Activating Nrf2 Pathway in a Mixed-Granulocytic Murine Asthma Model
This is still animal data, and whether the anti-inflammatory effects translate into meaningful clinical improvement in humans is an open question. But it adds another theoretical reason why ketamine could help in severe asthma, beyond just relaxing the muscles. Most standard asthma drugs either open the airways (beta-agonists) or reduce inflammation (steroids), but they work through different mechanisms than ketamine, which potentially makes it a useful add-on when the standard approach is failing.
When Ketamine Gets Used in Practice
Ketamine is not a first-line asthma drug. You would not reach for it during a typical flare-up, and it is not part of anyone’s daily controller regimen. It enters the picture during status asthmaticus, the most dangerous form of asthma attack, where the patient has not responded to repeated rounds of nebulized bronchodilators, systemic steroids, and sometimes magnesium sulfate or other adjuncts. At that point, the next step is often intubation and mechanical ventilation, which carry their own substantial risks in a patient with severely constricted airways.
Ketamine sits in a narrow window between “standard therapy has failed” and “we need to put this patient on a ventilator.” Pediatric critical care reviews list it alongside magnesium, aminophylline, and IV beta-agonists as one of the adjunctive medications that clinicians reach for when initial treatments are not working.7PubMed. Pharmacological Management of Pediatric Critical Asthma Several published case reports describe children and adults in respiratory failure who improved rapidly after receiving IV ketamine, avoiding intubation. In one pediatric case series, bolus doses followed by continuous infusion led to prompt improvement in children who were heading toward mechanical ventilation.8PubMed. Ketamine to avoid mechanical ventilation in severe pediatric asthma A similar adult case described an IV bolus of 0.75 mg/kg followed by a continuous drip that turned around a patient who had failed everything else.9PubMed. Intravenous ketamine in a dissociating dose as a temporizing measure to avoid mechanical ventilation in adult patient with severe asthma exacerbation
Ketamine also has practical advantages in the emergency setting. Unlike some sedatives that depress breathing, ketamine preserves respiratory drive and keeps protective airway reflexes largely intact. It raises blood pressure rather than dropping it, which matters when a crashing asthma patient may already be hemodynamically stressed. And it is considered an excellent sedative if intubation does become necessary, precisely because of its bronchodilatory properties.10Therapeutics and Clinical Risk Management. Is ketamine a lifesaving agent in childhood acute severe asthma?
What Randomized Trials Actually Show
Here is where the story gets frustrating. The pharmacology is compelling, the case reports are dramatic, and the biological rationale makes sense. But when researchers have tested ketamine in controlled trials with comparison groups, the results have been underwhelming.
A double-blind, placebo-controlled trial in adults with asthma exacerbations found that IV ketamine at a dose low enough to avoid dissociative side effects added no bronchodilatory benefit over standard emergency department therapy, and hospital admission rates were no different between groups.11PubMed. Randomized, double-blind, placebo-controlled trial of intravenous ketamine in acute asthma A pediatric trial using 0.2 mg/kg bolus followed by a 0.5 mg/kg per hour infusion for two hours likewise found no incremental benefit in children with moderately severe exacerbations.12PubMed. The efficacy of ketamine in pediatric emergency department patients who present with acute severe asthma When ketamine was compared head-to-head with aminophylline (another second-line option) in children with acute asthma, both drugs produced similar improvements in clinical scores, oxygen levels, and peak flow rates, with no significant differences between them.13PubMed Central. Ketamine versus aminophylline for acute asthma in children: A randomized, controlled trial
A 2022 systematic review pulled together the prospective studies and reached a blunt conclusion: across five randomized trials, there was no clear benefit from ketamine in patients with refractory severe asthma exacerbations, and some signals pointed toward side effects.14PubMed Central. Use of ketamine in patients with refractory severe asthma exacerbations: systematic review of prospective studies The review authors noted that the trials were small, used different dosing regimens, and measured different outcomes, making it hard to pool data meaningfully. But the overall direction of the evidence did not favor ketamine.
Why the Gap Between Case Reports and Trials
This disconnect puzzles clinicians who have personally watched a patient improve after ketamine. Several factors probably explain it. First, dose matters enormously. The trials that found no benefit generally used sub-dissociative doses to avoid psychological side effects, while many of the dramatic case reports used dissociative-range dosing. A patient receiving 0.2 mg/kg as a bolus in a trial is getting a fundamentally different exposure than someone receiving 1 to 2 mg/kg in a case report. One randomized trial that used doses of 0.3, 0.4, and 0.5 mg/kg in adults did find a significant increase in peak expiratory flow rate in the ketamine group compared to placebo, and the effect was larger at the higher doses.15PubMed Central. The Effect of Low-Dose Ketamine in Treating Acute Asthma Attack; a Randomized Clinical Trial That suggests there may be a dose threshold below which the drug simply does not produce enough bronchodilation to make a clinical difference.
Second, patient severity matters. The case reports that show the most dramatic responses tend to involve the sickest patients, people on the verge of respiratory failure. In those patients, even a modest improvement in airway caliber can be the difference between breathing on their own and needing a ventilator. A review of case reports in adults requiring mechanical ventilation found that all patients appeared to benefit from ketamine, with improved oxygenation and reduced bronchospasm.16PubMed. Does ketamine have a role in managing severe exacerbation of asthma in adults? The trials, by contrast, enrolled patients who were sick but usually not at death’s door, where the marginal benefit of one more bronchodilator on top of aggressive standard therapy is harder to detect.
Third, the standard therapy these patients already receive is genuinely effective. High-dose nebulized albuterol, ipratropium, and systemic steroids do a lot of heavy lifting. Adding another agent to an already aggressive regimen is working against a high baseline, which means you need very large trials to show a statistically meaningful difference, and those trials have not been done.
Nebulized Ketamine as an Alternative Route
Most of the clinical literature involves intravenous ketamine, but there is growing interest in delivering it as a nebulized mist directly into the lungs. The logic is appealing: deposit the drug right where the spasm and inflammation are, reduce the systemic dose, and avoid the need for IV access (which can be difficult in a distressed, dehydrated patient). A 2021 study found that nebulized ketamine improved peak flow rates, bronchospasm, and oxygen saturation while producing little to no respiratory depression, making it potentially safer than intravenous delivery.17PubMed Central. Asthmaticus and the use of ketamine nebulization and magnesium sulfate: current strategies and outcomes
A randomized trial comparing nebulized ketamine to IV magnesium sulfate in patients with corticosteroid-resistant acute severe asthma found that both treatments improved peak flow rates when added to standard therapy.18PubMed Central. The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial The nebulized route is still considered experimental, and the data are thin. But the early signals are encouraging enough that researchers continue to study it, particularly for settings where IV access is limited or where clinicians want to avoid the dissociative side effects that come with higher systemic doses.
Side Effects That Come With the Territory
Ketamine’s side-effect profile is one reason clinicians hesitate to use higher, potentially more effective doses. The psychological effects are the most concerning in an awake patient: vivid dreams, hallucinations, a sense of being detached from one’s body, and agitation. These are dose-dependent, meaning they get worse as the dose climbs. In a pediatric case series of status asthmaticus patients treated with IV ketamine, four patients experienced mild hallucinations, diffuse flushing, or moderate increases in blood pressure. All of these resolved either with a benzodiazepine or by stopping the infusion.19PubMed. Emergency department use of ketamine in pediatric status asthmaticus
Increased secretions in the airways are another practical concern. Ketamine stimulates salivary and bronchial glands, which can worsen obstruction in airways already narrowed by inflammation and mucus. Clinicians typically address this with glycopyrrolate or another drying agent given alongside the ketamine. The blood pressure elevation, while usually an advantage in a hemodynamically compromised patient, could be a problem in someone with uncontrolled hypertension or at risk for intracranial bleeding.
None of these side effects are typically life-threatening in a monitored setting, and most intensivists and emergency physicians are comfortable managing them. The real issue is that they limit the dose you can give to a conscious, spontaneously breathing patient, which may be exactly why the low-dose trials have been disappointing.
Pharmacokinetics in Critically Ill Patients
Ketamine behaves differently in critically ill patients compared to healthy volunteers. A detailed pharmacokinetic study of an adult with refractory status asthmaticus who required extracorporeal membrane oxygenation (ECMO) found that the drug’s volume of distribution was roughly 14 L/kg, about six and a half times larger than in healthy adults, with a half-life of about five hours.20Clinical Therapeutics. Pharmacokinetics of Ketamine at Dissociative Doses in an Adult Patient With Refractory Status Asthmaticus Receiving Extracorporeal Membrane Oxygenation Therapy The expanded distribution volume was similar to values seen in other critically ill patients not on ECMO, suggesting that severe illness itself, not just the ECMO circuit, changes how the drug distributes through the body. For clinicians, this means dosing regimens derived from healthy-volunteer studies may not apply to the sickest asthma patients, and higher or more frequent dosing may be needed to achieve therapeutic levels.
Where Ketamine Fits in Asthma Guidelines
Despite its long history of use, ketamine does not have a prominent place in major asthma treatment guidelines. Most expert consensus documents mention it only briefly, if at all, as one of several last-resort adjuncts. The evidence base simply is not strong enough to give it a firm recommendation. Pediatric critical care reviews note that practitioners “often prescribe” it as an adjunctive medication when symptoms do not improve with first-line agents, but this language reflects practice patterns more than formal guideline endorsement.21PubMed. Pharmacological Management of Pediatric Critical Asthma
In practice, ketamine occupies a peculiar niche. Almost every emergency physician and intensivist knows about its bronchodilatory properties, and many have anecdotal experience using it successfully. But the randomized trial data do not support routine use, and the systematic review evidence actively discourages it for refractory exacerbations.22PubMed Central. Use of ketamine in patients with refractory severe asthma exacerbations: systematic review of prospective studies This leaves individual clinicians to make judgment calls, typically reserving ketamine for the most dire situations where the alternative is intubation and mechanical ventilation.
Ketamine as a Sedative for Intubation in Asthma
Even clinicians who are skeptical about ketamine’s role as a bronchodilator tend to agree on one point: if you do need to intubate a patient in status asthmaticus, ketamine is probably the best induction agent for the job. Most other sedatives used for rapid sequence intubation, such as propofol, can drop blood pressure, which is risky in a patient whose hemodynamics may already be compromised by air trapping and high intrathoracic pressure. Ketamine, by contrast, supports blood pressure and may actively help open the airways during and after the intubation itself.23Therapeutics and Clinical Risk Management. Is ketamine a lifesaving agent in childhood acute severe asthma? This is arguably the least controversial use of ketamine in asthma management, and one where its properties align most cleanly with clinical needs.
The distinction matters because the question “should we use ketamine for this asthma patient?” has two different answers depending on what you mean. As an add-on bronchodilator to prevent intubation, the evidence is weak. As the sedative of choice if intubation becomes necessary, the rationale is strong and widely accepted. These are different clinical scenarios, and conflating them has contributed to confusion about what the literature actually supports.
Open Questions and Ongoing Research
The biggest unanswered question is whether a well-designed, adequately powered trial using dissociative-range doses in truly refractory patients would show a clear benefit. Most existing trials used low doses in moderately ill patients, which may have set ketamine up to fail. Researchers and clinicians have pointed out that the ideal study population, patients on the verge of respiratory failure, is both small and ethically challenging to enroll in a placebo-controlled trial. Nobody wants to randomize a dying patient to receive saline instead of a drug that might help.
Nebulized delivery remains an active area of investigation. If the route can deliver meaningful bronchodilation with fewer systemic side effects, it could shift the risk-benefit calculation for a broader population of asthma patients. The anti-inflammatory effects identified in animal models also warrant further study; if ketamine addresses both the smooth-muscle and inflammatory components of an asthma attack, its value in acute exacerbations could be greater than pure bronchodilation data suggest. For now, ketamine remains what it has been for decades: a drug that every emergency clinician has in their back pocket, supported more by pharmacology and experience than by the kind of trial evidence that would put it into treatment algorithms alongside magnesium and ipratropium.